Basiliximab reduces acute liver allograft rejection in pediatric patients.

Strassburg, A; Pfister, E D; Arning, A; Nashan, B; Ehrich, J H H; Melter, M

Strassburg, A; Pfister, E D; Arning, A; Nashan, B; Ehrich, J H H; Melter, M.

Affiliation

Strassburg A; Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital, Hannover Medical School, Hannover, Germany.

Transplant Proc ; 34(6): 2374-5, 2002 Sep.

Article in En | MEDLINE | ID: mdl-12270443

Subject(s)

Antibodies, Monoclonal/therapeutic use; Graft Rejection/prevention & control; Immunosuppressive Agents/therapeutic use; Liver Transplantation/immunology; Recombinant Fusion Proteins; Adolescent; Basiliximab; Child; Child, Preschool; Cyclosporine/therapeutic use; Female; Follow-Up Studies; Humans; Infant; Liver Diseases/surgery; Male; Retrospective Studies; Tacrolimus/therapeutic use; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Liver Transplantation / Graft Rejection / Immunosuppressive Agents / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Transplant Proc Year: 2002 Document type: Article Affiliation country: Germany

Search on Google

Add to My VHL

XML

PubMed Links